FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy Wednesday – Rare Disease Report
Rare Disease Report |
FDA Advisory Board and Novartis to Discuss Leukemia Gene Therapy Wednesday
Rare Disease Report On Wednesday, the Oncology Drug Advisory Committee for the U.S. Food and Drug Administration (FDA) will review Novartis AG's experimental gene therapy drug tisagenlecleucel, with a specific focus on the safety of the potential leukemia treatment. Before Key Meeting, FDA Stresses Risks of Novartis CAR-T Cancer Therapy BRIEF-Inficon expects H1 sales of around $182 million |
